Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Mastocytosis, Systemic 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Hairy Cell 1Hodgkin Disease 1Hematologic Neoplasms 1Burkitt Lymphoma 1Breast Neoplasms 1Breast Carcinoma In Situ 1Blastic Plasmacytoid Dendritic Cell Neoplasm 1

Interventions

avapritinib 4dexamethasone acetate 1dexamethasone 21-phosphate 1auricularum 1Thalidomide 1Ranitidine 1Ibuprofen 1Diphenhydramine 1Dexamethasone 1Denosumab 1Calcium Dobesilate 1Acetaminophen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Mastocytosis, Systemic × Ranitidine × 1 year × Clear all
NCT04681105 2026-01-28

Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies

City of Hope Medical Center

Phase 1 Completed
13 enrolled
LymphoidMyeloidOther hematologic neoplasm

Blastic Plasmacytoid Dendritic Cell Neoplasm, Burkitt Lymphoma, Hodgkin Disease, Leukemia, Hairy Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Hematologic Neoplasms, Mastocytosis, Systemic, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡